menu search

ANL / IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO
Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell cancer. The global market for head and neck cancer treatments is expected to reach $3.5 billion by 2030. Read More
Posted: Aug 11 2023, 14:16
Author Name: Seeking Alpha
Views: 092027

ANL News  

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

By Seeking Alpha
September 30, 2023

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

The third quarter wrapped up with four IPOs and eight pipeline additions. Eight issuers submitted initial filings this past week. The October IPO mark more_horizontal

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

By Seeking Alpha
August 12, 2023

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time thr more_horizontal

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

By Seeking Alpha
August 11, 2023

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials more_horizontal

Cancer treatment company Adlai Nortye sets terms in IPO

By Market Watch
August 11, 2023

Cancer treatment company Adlai Nortye sets terms in IPO

Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its ini more_horizontal


Search within

Pages Search Results: